Tory MPs have urged the Government to take London out of lockdown as soon as possible after infection rates fell in most boroughs, including Bromley and Lewisham.

According to the latest figures, 18 boroughs saw reduced rates in the week leading up to November 4 compared with the previous seven days, with Bromley and Lewisham at around 100 new cases a week per 100,000 population.

MPs are lobbying the Government to place London under the lightest restrictions from December 2, but still back the current lockdown period to halt the rise in hospitalisations.

Sir Bob Neill told the Evening Standard: “If it’s falling and that demonstrates a clear trend, they should consider taking London out earlier than December 2.

“If they don’t, on the evidence we have got so far, that would point towards us going into Tier 1.”

Bromley now has the lowest infection rate in London, at 96.3 new cases per 100,000, down from 119.8 the previous week.

Lewisham is slightly above, at 100.1 new cases, down from 109.2 the week before.

Nickie Aiken, Conservative MP for the Cities of London and Westminster, said: “I’m urging ministers to seriously consider London returning to the lowest tier when lockdown ends on December 2 if our numbers continue to fall.”

Prime Minister Boris Johnson will hold a Downing Street press conference at 5pm after Pharmaceutical company Pfizer announced its coronavirus vaccine candidate is more than 90% effective in preventing Covid-19 during a major trial.

The firm, which is developing the mRNA-based vaccine with BioNTech, said the results were from a independent interim analysis of the results of its phase three clinical study.

Dr Albert Bourla, Pfizer chairman and CEO, said: "Today is a great day for science and humanity. The first set of results from our phase three Covid-19 vaccine trial provides the initial evidence of our vaccine's ability to prevent Covid-19.

"We are reaching this critical milestone in our vaccine development programme at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen.

"With today's news, we are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis.

"We look forward to sharing additional efficacy and safety data generated from thousands of participants in the coming weeks.

"I want to thank the thousands of people who volunteered to participate in the clinical trial, our academic collaborators and investigators at the study sites, and our colleagues and collaborators around the world who are dedicating their time to this crucial endeavour.

"We could not have come this far without the tremendous commitment of everyone involved."